Survival outcomes in patients treated with or without BT. Kaplan-Meier estimates of PFS (A) and OS (B) in patients with R/R LBCL who underwent leukapheresis according to receipt of BT, and estimates of PFS (C) and OS (D) in R/R LBCL patients who received CAR T-cell therapy. The numbers of patients at risk in 5-month intervals are indicated.